- Home
- TEVA
as 07-26-2024 4:00pm EST
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Upcoming Earnings Alert:
Get ready for potential market movements as Teva Pharmaceutical Industries Limited TEVA prepares to release earnings report on 31 Jul 2024.
| Founded: | 1901 | Country: | Israel |
| Employees: | N/A | City: | TEL AVIV |
| Market Cap: | 19.1B | IPO Year: | N/A |
| Target Price: | $18.38 | AVG Volume (30 days): | 8.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.06 - $17.69 | Next Earning Date: | 07-31-2024 |
| Revenue: | $16,004,000,000 | Revenue Growth: | 7.22% |
| Revenue Growth (this year): | 2.64% | Revenue Growth (next year): | 3.71% |
Latest Teva Pharmaceutical Industries Limited News
TEVA Breaking Stock News: Dive into TEVA Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Sanofi, Teva Pharmaceuticals Expect Topline Results From Phase 2b Duvakitug Trial in Q4
Business Wire
2 days ago
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
Zacks
7 days ago
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
Clinical Trials Arena
8 days ago
Teva reports positive data from Phase III paediatric migraine prevention trial
MT Newswires
8 days ago
Teva Pharmaceutical Says Trial of Ajovy to Prevent Episodic Migraine in Children Reaches Primary Endpoint
Business Wire
8 days ago
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
Motley Fool
10 days ago
3 No-Brainer Stocks to Buy With $200 Right Now
Morningstar Research
14 days ago
Analyst Report: Teva Pharmaceutical Industries Limited
Compare TEVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TEVA Teva Pharmaceutical Industries Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.